Research progress on the pathogenesis of hypertensive nephropathy

doi:10.3877/cma.j.issn.2095-3216.2023.06.007

Abstract

Abstract:

The pathogenesis of hypertensive nephropathy is quite complex. In addition to traditional mechanisms such as the renin-angiotensin-aldosterone system (RAAS), oxidative stress, and inflammatory response, other emerging aspects have also received increasing attention recently, including exosomes, ferroptosis, gut microbiota disorder, and non-coding RNA, etc. This article reviewed the research progress of traditional and emerging pathogenesis of hypertensive nephropathy, in order to provide reference for the clinical diagnosis and treatment of hypertensive nephropathy.

Key words: Hypertensive nephropathy, Pathogenesis, Exosomes, Ferroptosis, Gut microbiota, Non-coding RNA

Xinxin Hu, Xiaofan Meng, Zhaoan Guo. Research progress on the pathogenesis of hypertensive nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(06): 339-343.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2023.06.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2023/V12/I06/339

Figures/Tables 1

References 34

[1]	Yang C, Gao B, Zhao X, et al. Executive summary for China Kidney Disease Network (CK-NET) 2016 annual data report [J]. Kidney Int, 2020, 98(6): 1419-1423.
[2]	You S, Xu J, Wu B, et al. Comprehensive bioinformatics analysis identifies POLR2I as a key gene in the pathogenesis of hypertensive nephropathy [J]. Front Genet, 2021, 12: 698570.
[3]	Li D, Li B, Peng L, et al. Therapeutic efficacy of piperazine ferulate combined with irbesartan in diabetic nephropathy: a systematic review and meta-analysis [J]. Clin Ther, 2020, 42(11): 2196-2212.
[4]	Cuadrado A, Manda G, Hassan A, et al. Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach [J]. Pharmacol Rev, 2018, 70(2): 348-383.
[5]	Zhang C, Fang X, Zhang H, et al. Genetic susceptibility of hypertension-induced kidney disease [J]. Physiol Rep, 2021, 9(1): 14688-14703.
[6]	Stanciu S, Rusu E, Miricescu D, et al. Links between metabolic syndrome and hypertension: the relationship with the current antidiabetic drugs [J]. Metabolites, 2023, 13(1): 87.
[7]	曾春雨. 高血压肾病[M]. 重庆：重庆大学出版社，2020: 86.
[8]	Osada-Oka M, Shiota M, Izumi Y, et al. Macrophage-derived exosomes induce inflammatory factors in endothelial cells under hypertensive conditions [J]. Hypertens Res, 2017, 40(4): 353-360.
[9]	Li ZL, Lv LL, Tang TT, et al. HIF-1alpha inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation [J]. Kidney Int, 2019, 95(2): 388-404.
[10]	Perez-Hernandez J, Riffo-Campos AL, Ortega A, et al. Urinary- and plasma-derived exosomes reveal a distinct microRNA signature associated with albuminuria in hypertension [J]. Hypertension, 2021, 77(3): 960-971.
[11]	Li YF, Chakraborty A, Broughton BRS, et al. Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice [J]. Biomed Pharmacother, 2021, 144: 112256.
[12]	Cambier L, Giani JF, Liu WX, et al. Angiotensin Ⅱ-induced end-organ damage in mice is attenuated by human exosomes and by an exosomal Y RNA fragment [J]. Hypertension, 2018, 72(2): 370-380.
[13]	Zhou J, Tan Y, Wang R, et al. Role of ferroptosis in fibrotic diseases [J]. J Inflamm Res, 2022, 15: 3689-3708.
[14]	Wang JY, Wang YQ, Liu Y, et al. Ferroptosis, a new target for treatment of renal injury and fibrosis in a 5/6 nephrectomy-induced CKD rat model [J]. Cell Death Discov, 2022, 8(1): 127-137.
[15]	Aghsaeifard Z, Alizadeh R, Bagheri N. Association between neutrophil gelatinase-associated lipocalin (NGAL) and iron profile in chronic renal disease [J]. Arch Physiol Biochem, 2022, 128(3): 703-707.
[16]	Zhou L, Xue X, Hou Q, et al. Targeting ferroptosis attenuates interstitial inflammation and kidney fibrosis [J]. Kidney Dis, 2022, 8(1): 57-71.
[17]	Chen YZ, Wang K, Yang J, et al. Mechanism of ferroptosis in hypertensive nephropathy [J]. Transl Androl Urol, 2022, 11(5): 617-626.
[18]	韩聪，姜月华，李伟. miRNA-21在高血压肾损害中的作用机制及研究进展[J]. 中华高血压杂志，2019, 27(8): 728-733.
[19]	韩聪，姜月华，李伟. miRNA-29在高血压肾损害中的研究进展[J]. 中华高血压杂志，2019, 27(7): 624-629.
[20]	Arishe OO, Priviero F, Wilczynski SA, et al. Exosomes as intercellular messengers in hypertension [J]. Int J Mol Sci, 2021, 22(21): 11685.
[21]	Jiang XY, Ning Q. The mechanisms of lncRNA GAS5 in cardiovascular cells and its potential as novel therapeutic target [J]. J Drug Target, 2020, 28(10): 1012-1017.
[22]	Qian W, Zheng ZQ, Nie JG, et al. LncRNA SNHG12 alleviates hypertensive vascular endothelial injury through miR-25-3p/SIRT6 pathway [J]. J Leukoc Biol, 2021, 110(4): 651-661.
[23]	Lu CS, Chen BC, Chen CC, et al. CircNr1h4 regulates the pathological process of renal injury in salt-sensitive hypertensive mice by targeting miR-155-5p [J]. J Cell Mol Med, 2020, 24(2): 1700-1712.
[24]	Lin Y, Wu SH, Wang XH, et al. Associations of imbalance of intestinal flora with severity of disease, inflammatory factors, adiponectin, and vascular endothelial function of hypertension patients [J]. Kaohsiung J Med Sci, 2022, 38(2): 165-173.
[25]	Chi MX, Ma K, Wang J, et al. The immunomodulatory effect of the gut microbiota in kidney disease [J]. J Immunol Res, 2021, 2021: 5516035.
[26]	Lin H, Liu TF, Li X, et al. The role of gut microbiota metabolite trimethylamine N-oxide in functional impairment of bone marrow mesenchymal stem cells in osteoporosis disease [J]. Ann Transl Me, 2020, 8(16): 1009.
[27]	Monteiro EB, Soares EDR, Trindade PL, et al. Uraemic toxin-induced inflammation and oxidative stress in human endothelial cells: protective effect of polyphenol-rich extract from açaí [J]. Exp Physiol, 2020, 105(3): 542-551.
[28]	Lv J, Chen J, Wang M, et al. Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization [J]. Aging (Albany, NY), 2020, 12(10): 9139-9150.
[29]	李召荣，毕慧欣. 硫酸吲哚酚引起慢性肾脏病血管钙化机制的研究进展[J]. 中国中西医结合肾病杂志，2021, 22(12): 1119-1121.
[30]	Chen L, He FJ, Dong Y, et al. Modest sodium reduction increases circulating short-chain fatty acids in untreated hypertensives [J]. Hypertension, 2020, 76(1): 73-79.
[31]	Felizardo RJF, Almeida DC, Pereira RL, et al. Gut microbial metabolite butyrate protects against proteinuric kidney disease through epigenetic- and GPR109a-mediated mechanisms [J]. FASEB J, 2019, 33(11): 11894-11908.
[32]	Tilves C, Yeh HC, Maruthur N, et al. Increases in circulating and fecal butyrate are associated with reduced blood pressure and hypertension: results from the SPIRIT trial [J]. J Am Heart Assoc, 2022, 11(13): e024763.
[33]	Lu CC, Hu ZB, Wang R, et al. Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy [J]. Acta Pharmacol Sin, 2020, 41(8): 1111-1118.
[34]	Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation [J]. Proc Natl Acad Sci USA, 2013, 110(11): 4410-4415.

Please choose a citation manager

Content to export